Recent Share Transactions by Genmab's Managerial Employees
Genmab A/S, a prominent biotechnology company, is taking significant steps to ensure transparency regarding share transactions involving its managerial employees and their closely associated individuals. The recent disclosures related to transactions made by these individuals provide valuable insights into the company’s governance and commitment to ethical practices.
Understanding the Disclosure Process
In line with regulatory requirements, Genmab disclosed information about transactions made by its managerial employees under Article 19 of Regulation No. 596/2014 on Market Abuse and implementing regulations. This is aimed at promoting transparent trading and ensuring stakeholders are well-informed about the actions of key personnel within the company.
Power of Attorney for Disclosure
It is noteworthy that Genmab’s managerial employees have granted the company power of attorney to publish the details of their share trading activities. This proactive measure signifies the company's emphasis on accountability and openness, reflecting its commitment to integrity in managing investor relations.
About Genmab: A Leader in Biotech Innovation
Genmab A/S thrives on its mission to develop innovative antibody therapeutics that enhance the lives of patients with serious ailments. With a heritage of over 25 years in biotechnology, the firm has consistently advanced next-generation antibody technology through a talented and dedicated team. This team is driven by a desire to achieve life-changing results for individuals battling cancer and other critical diseases.
The company's diverse pipeline showcases various therapeutic solutions, notably including bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators. By 2030, Genmab envisions creating what they term knock-your-socks-off (KYSO) antibody medicines®, a testament to their ambitious goals in the therapy landscape.
Global Presence and Reach
Founded in 1999 and based in Copenhagen, Denmark, Genmab has successfully extended its footprint across North America, Europe, and Asia Pacific. This international presence not only reinforces its market position but also enhances collaboration and innovation through diverse global networks.
Contact Information for Stakeholders
Effective communication with stakeholders is integral to Genmab’s operations. For inquiries, the company maintains dedicated contacts:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What is Genmab A/S known for?
Genmab A/S specializes in developing innovative antibody therapeutics aimed at improving patient outcomes in cancer and serious diseases.
What recent actions have managerial employees taken?
Managerial employees of Genmab have recently conducted share transactions, which were disclosed as per regulatory requirements, indicating the company's commitment to transparency.
How long has Genmab been in operation?
Genmab was established in 1999 and has over 25 years of experience in the biotechnology sector.
What are KYSO antibody medicines?
KYSO (knock-your-socks-off) antibody medicines are a part of Genmab's vision for creating exceptionally effective therapeutic solutions by 2030.
Where is Genmab headquartered?
Genmab is headquartered in Copenhagen, Denmark, and has a significant global presence across multiple regions.
